12,259 Shares in Gilead Sciences, Inc. $GILD Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,259 shares of the biopharmaceutical company’s stock, valued at approximately $1,361,000.

Several other institutional investors also recently made changes to their positions in the stock. Rothschild Investment LLC lifted its holdings in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares during the last quarter. Hemington Wealth Management increased its position in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares during the period. Ignite Planners LLC increased its position in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the period. Archer Investment Corp lifted its stake in Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 87 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Gilead Sciences by 0.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock valued at $3,912,000 after acquiring an additional 87 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

GILD opened at $147.12 on Thursday. The company has a market capitalization of $182.53 billion, a price-to-earnings ratio of 21.73, a price-to-earnings-growth ratio of 1.76 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The business has a 50 day moving average price of $135.16 and a two-hundred day moving average price of $124.44.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the firm earned $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. UBS Group increased their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley raised their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Leerink Partners lifted their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Argus increased their price objective on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, Oppenheimer raised their target price on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New Phase 3 results (ARTISTRY‑1 and ARTISTRY‑2) show Gilead’s investigational single‑tablet bictegravir/lenacapavir regimen maintained virological suppression in people switching therapy — a meaningful data point for switching patients and long‑term market share. Gilead’s Single-Tablet Regimen Maintained Virological Suppression (BusinessWire)
• Positive Sentiment: Independent coverage reports the experimental single‑tablet regimen was generally well tolerated with low discontinuation rates, supporting commercial viability if approved. Gilead’s experimental HIV treatment shows low discontinuation rates in studies (Reuters)
• Positive Sentiment: Gilead agreed to acquire Arcellx for $7.8B to gain full control of anito‑cel, strengthening its cell therapy / oncology pipeline — a strategic bolt‑on that could drive long‑term growth beyond HIV. Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy (Benzinga)
• Positive Sentiment: Analyst activity is supportive: Needham reaffirmed a Buy and at least one outlet reports an 11.7% higher price target — signals that sell‑side expectations are improving. Needham & Company LLC Reaffirms Buy Rating for Gilead Sciences (AmericanBankingNews)
• Positive Sentiment: Market commentary notes a raised price target to about $159, reflecting bullish analyst revisions following the recent data and deal. Gilead Sciences (GILD) price target increased by 11.73% to 159.01 (MSN)
• Neutral Sentiment: Broader market/sector headlines (e.g., macro or AI “halo” trade commentary) are likely distracting investors but are not specific to Gilead’s fundamentals. Hypothetical AI Doomsday Scenario Lights Up Wall Street’s HALO Trade (The Daily Upside)
• Negative Sentiment: Competitive risk: Merck’s two‑drug HIV regimen reportedly matched Gilead’s Biktarvy in Phase 3 and is under FDA review — increased competition in HIV could pressure long‑run pricing and market share. Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. (Yahoo/WSJ)

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the sale, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 317,085 shares of company stock valued at $44,734,886 over the last 90 days. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.